No Brainer8 Aug 2024 12:47
Lost my shirt on oil & Gas over the years but medical care products rarely let you down IMO.
You can't argue with the latest comms issued especially with the Proffesor Newman's comments:
James Cheek, CEO of genedrive plc, said: “We are delighted with this final guidance from NICE recommending
implementation of CYP2C19 genotype-guided use of Clopidogrel in IS and TIA patients in the NHS to reduce risk of
recurrent strokes, and recommendation of our CYP2C19 ID-kit as the point-of-care interventional platform of choice.
This represents a key milestone in our commercialisation plans for the product, and further solidifies our business
strategy of leading provision of cost-effective solutions for pharmacogenetics in time critical emergency healthcare
situations. We are proud to be at the forefront of the emergence of near-patient genetic testing in emergency
healthcare to facilitate optimal personalised therapeutic choices and ultimately improve patient outcomes.”
Professor Bill Newman, Professor of Translational Genomic Medicine at the University of Manchester and Lead
of the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation at Manchester University
NHS Foundation Trust, said: “To ensure that patients receive the correct treatment to reduce the risk of them having
a further stroke after an initial episode, we need to use a rapid genetic test. The development of this new point-ofcare diagnostic has the potential to significantly improve care for tens of thousands of patients after a stroke. As
part of the DEVOTE project we have been delighted to have worked with genedrive to generate the evidence for this
test to become available to patients.”
Sign In
Follow the stocks
